Evaluation of a new automated third-generation anti-HCV enzyme immunoassay

Journal of Clinical Laboratory Analysis

Volumn 10, Issue 5, 1996, Pages 269-276

  Lavanchy, D ^a   Steinmann, J ^b   Moritz A ^c   Frei, P C ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Staatliches Hygiene Institut   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

automation; diagnosis laboratory; hepatitis C viruses; immunoassay

Indexed keywords

HEPATITIS C ANTIBODY;

ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; HEPATITIS; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; MAJOR CLINICAL STUDY; SCREENING TEST;

HEPATITIS C ANTIBODIES; HUMANS; IMMUNOENZYME TECHNIQUES; SENSITIVITY AND SPECIFICITY;

HEPATITIS C VIRUS; MUREX;

EID: 0029841889     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(1996)10:5<269::AID-JCLA7>3.0.CO;2-3     Document Type: Article

References (15)

1. Alter HJ, Purcell RH, Shih JW, Melpolder MT, Houghton M, Qui-Lim C, Kuo G: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B viral hepatitis. N Engl J Med 321:1494-1500, 1989.
2. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura JL, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F. Colombo M, Lee W-S. Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364, 1989.
3. Alter MJ: Chronic consequences of non-A, non-B Hepatitis. In Current Perspectives in Hepatology. LB Secff, JH Lewis, eds. Plenum, New York, 1989, p 83-97.
4. Chokephaibulkit K, Painter PC, Patamasucon P: Overview of hepatitis C. Clin Lab Med 23:798-803, 1992.
5. Meisel H: Hepatitis-C-virus. In vitro Diagn Nachr Diagn Bibl 20:1-12, 1994.
6. Kamel MA, Ghaffar YA, Wasef MA, Wright M, Clark LC, DeWolfe Miller F: High HCV prevalence in Egyptian blood donors. Lancet 340:427, 1992.
7. Zweig MH, Campbell G: Receiver-operating characteristics (ROC) plots: A fundamental evaluation tool in clinical medicine, Clin Chem 39:561-577, 1993.
8. Busch MP, Tobler L, Quan S, Wilber JC, Johnson P, Polito A, Steane E, Zola A, Bahl C, Nelles M, Lee SR: A pattern of 5-1-1 and c100-3 only on hepatitis C virus (HCV) recombinant immunoblot assay does not reflect HCV infection in blood donors. Transfusion 33:84-88, 1993.
9. Waumans L, Claeys H, Verhaert H, Mertens W, Vermylen C: Hepatitis C virus confirmation in blood donor screening. Vox: Sang 64:145-149, 1993.
10. Perrons CJ, Garson JA: Hepatitis C virus blood donor screening: recombinant immunoblot assay interpretation re-examined. Vox Sang 64:253, 1993.
11. Bresters D, Zaaijer HL, Cuypers HT, Reesink HW, Winkel IN, van Exel Oehlers PJ, van Drimmelen AA, Jansen PL, van der Poel CL, Lelie PN: Recombinant immunoblot assay reaction patterns and hepatitis C virus RNA in blood donors and non-A, non-B hepatitis patients. Transfusion 33:634-638, 1993.
12. Kolho E, Naukkarinen R, Krusius T: Transmission of HCV infection by RIBA indeterminate and positive blood units. Transfus Med 2:243-248, 1992.
13. Lavanchy D, Mayerat C, Morel B, Schneider P, Zufferey C, Gonvers JJ, Pécoud A, Frei PC: Evaluation of third-generation assays for the detection of anti-HCV antibodies and comparison with the presence of HCV RNA in blood donors reactive to C100-3 antigen. J Clin Microbiol 32:2272-2275, 1994.
14. Buffet C, Charnaux N, Laurent-Puig P, Chopineau S, Quichou JP, Briantais MJ, Dussaix E: Enhanced detection of antibodies to hepatitis C virus by use of a third-generation recombinant immunoblot assay. J Med Virol 43:259-261, 1994.
15. Pawlotsky JM, Fleury A, Choukroun V, Deforges L, Roudot-Thoraval F, Aumont P, Duval J, Dhumeaux D: Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA. J Clin Microbiol 32:1357-1359, 1994.